Description du projet
Détection ultrasensible et rapide des récidives du cancer de la tête et du cou
La récidive survenant après une rémission initiale est la principale cause de décès liés au cancer. La start-up néerlandaise Cyclomics a mis au point une technologie de détection de l’ADN tumoral circulant, signe d’une récidive du cancer de la tête et du cou, via l’identification des mutations du gène TP53. Sa méthodologie de séquençage innovante permet une détection fiable, rapide et ultrasensible d’une récidive de cancer à partir d’échantillons de sang/de biopsies liquides. La majorité des patients atteints de cancer de la tête et du cou sont porteurs de mutations spécifiques de l’ADN dans le gène TP53, l’application de cette nouvelle technologie représente donc également une opportunité de marché considérable pour l’entreprise. L’étude de faisabilité ONCOTECT, financée par l’UE, entend apporter une vision détaillée critique de la stratégie de commercialisation.
Objectif
Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies).
The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods.
Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
3531 BX UTRECHT
Pays-Bas
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.